These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-005051-34 Efficacy and safety study of vWF SD-35-DH (WILFACTIN) in children under 6 years of age bad-data
Reported results 2005-001746-17 EFFICACY AND SAFETY STUDY OF vWF SD-35-DH (WILFACTIN) IN PATIENTS UNDER LONG TERM PROPHYLAXIS 2012-07-17 due-trials
Reported results 2007-001280-30 INTERNATIONAL NON -CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF FIBRINOGENE T-I IN ADOLESCENTS AND ADULTS WITH AFIBRINOGENAEMIA OR SEVERE HYPOFIBRINOGENAEMIA UNDERGOING SURGERY 2013-11-08 due-trials
Reported results 2007-001410-17 LONG-TERM SAFETY AND EFFICACY STUDY OF IGNG, A NEW LIQUID PREPARATION OF HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE, ADMINISTERED IN CURRENT PRACTICE TO PRIMARY IMMUNODEFICIENT PATIENTS 2011-01-28 due-trials
Reported results 2007-004116-32 EFFICACY AND SAFETY STUDY OF WILFACTIN ADMINISTERED BY CONTINUOUS INFUSION IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING MAJOR SURGICAL PROCEDURES 2013-03-07 due-trials
Exempt, with results 2008-002601-40 Open, non-controlled, multicentre, first-in-man study using escalating doses of LFB-R603 in patients with advanced stage B-Chronic lymphocytic leukemia 2011-08-23 not-yet-due
Ongoing 2008-007110-29 An international randomised, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dosing regimens of FIBRINOGENE T1 in the treatment of peri-operative bleeding associated with... not-yet-due
Reported results 2009-011017-24 A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac®, a pol... 2011-07-15 due-trials
Ongoing 2009-012036-32 SAFETY STUDY OF IGNG, A NEW LIQUID PREPARATION OF HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE, WHEN ADMINISTERED TO PRIMARY IMMUNODEFICIENT PATIENTS, AT A PROGRESSIVELY INCREASED FLOW RATE not-yet-due
Exempt, with results 2009-013227-28 A Double-Blind, Randomized, Crossover Study of the Recovery of FACTANE 100 versus 200 IU/ml followed by an Open-Label Safety Study of FACTANE 200 IU/ml in Previously Treated Patients With Severe (FVI... 2010-11-25 not-yet-due
Trial is partly outside EEC, and reported results 2010-023483-41 A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID) 2013-03-27 bad-data
Reported results 2010-023666-46 EFFICACY AND SAFETY STUDY OF FACTANE 200 IU/ml ADMINISTERED BY CONTINUOUS INFUSION IN SEVERE HAEMOPHILIA A PATIENTS DURING MAJOR SURGICAL PROCEDURES Ocena skuteczności i bezpieczeństwa preparatu FA... 2012-07-12 due-trials
Reported results 2011-001354-29 An open-label, multicentre efficacy and safety study of I10E in patients with primary Immune ThrombocytoPenia (ITP) Studio multicentrico, in aperto, sull`™efficacia e la sicurezza di I10E in pazie... 2013-05-07 due-trials
Reported results 2012-001995-12 A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in pat... 2016-07-01 due-trials
Reported results 2012-001996-34 A comparative, double-blind, randomised, multicentre efficacy and safety study of ClairYg® versus Tégéline® in maintenance treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 2015-06-08 due-trials
Trial is partly outside EEC, and reported results 2013-000261-36 Clinical pharmacology, efficacy and safety study of FGTW in paediatric patients with severe congenital fibrinogen deficiency Etude de pharmacologie clinique, d’efficacité et de tolérance du FGTW ch... 2015-12-11 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-000620-34 A Multicentre Phase III Study on the Efficacy, Safety and Pharmacokinetics of LFB-IgSC in Patients with Primary Immunodeficiency (PID) Syndromes 2014-03-14 bad-data
Reported results 2013-002484-26 A RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ON THE EFFICACY AND SAFETY OF A THERAPEUTIC STRATEGY OF POST PARTUM HAEMORRHAGE COMPARING EARLY ADMINISTRATION OF HUMAN FIBRINOGEN VER... 2018-08-06 due-trials
Reported results 2013-005557-73 An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy 2017-09-29 due-trials
Reported results 2013-005558-31 International, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM study I10E-130... 2017-07-28 due-trials
Reported results 2015-000958-38 A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients from birth to <12 years old with Inhibitors... 2017-06-30 due-trials
Other 2022-001759-17 A multicenter, randomized, double-blind, placebo-controlled, parallel, phase 3 study to assess the efficacy and safety of fibrinogen concentrate (FGTW) in the management of bleeding in patients underg... not-yet-due